Medicine and Dentistry
Ganglioglioma
100%
Glioblastoma
88%
Neoplasm
60%
Clinical Trial
26%
Central Nervous System Cancer
26%
Temozolomide
26%
Drug Megadose
25%
Biological Marker
22%
Methotrexate
21%
Primary Central Nervous System Lymphoma
21%
Magnetic Resonance Imaging
20%
Brain Tumor
18%
Metastatic Carcinoma
17%
Oligodendroglioma
16%
Neuro-Oncology
16%
Tumor Recurrence
15%
Malignant Neoplasm
15%
Rituximab
12%
Progression Free Survival
12%
Central Nervous System
11%
Immunohistochemistry
11%
Central Nervous System Tumor
10%
Disease
10%
Chemoradiotherapy
10%
Radiation Therapy
10%
Quality of Life
10%
Quantitative Imaging
9%
Overall Survival
9%
Treatment Effect
9%
Fluorine-18
9%
Surgery
8%
Cancer
8%
Real Time Polymerase Chain Reaction
8%
Proton Transport
8%
Radiation Dose Escalation
8%
Carboxamide
8%
in Situ Hybridization
8%
Cytomegalovirus
8%
Cerebrospinal Fluid
8%
Epileptic Absence
8%
Recurrent Disease
8%
Immune-Related Adverse Events
7%
Oncologist
7%
Immune Checkpoint Inhibitor
7%
Biopsy
7%
Lomustine
7%
Solid Malignant Neoplasm
7%
Bevacizumab
6%
Isocitrate Dehydrogenase 1
6%
Lymphocyte
6%
Keyphrases
Glioblastoma
61%
High-grade Glioma
43%
Primary Central Nervous System Lymphoma (PCNSL)
29%
Temozolomide
25%
Tumor
24%
Oligodendroglioma
22%
Neuro-oncology
22%
Newly Diagnosed
19%
High-dose Methotrexate (HD-MTX)
19%
Central Nervous System Cancer
16%
Glioma
15%
Newly Diagnosed Glioblastoma
14%
Central Nervous System Tumors
13%
Chemotherapy
12%
Brain Tumor Patients
12%
Primary Brain Tumor
11%
Chemoradiation
11%
Isocitrate Dehydrogenase 1 (IDH1)
11%
Glioma Patients
10%
Astrocytoma
10%
Tumor DNA
10%
Cerebrospinal Fluid
10%
Immunohistochemistry
9%
Overall Survival
9%
Post-irradiation
9%
Rituximab
9%
Anaplastic Oligodendroglioma
9%
Progression-free Survival
9%
Central Nervous System
9%
Molecular Diagnostics
9%
Clinical Trials
9%
Adult Brain Tumors
9%
Spectroscopic MRI
9%
Treatment Effect
8%
Molecular Markers
8%
Solid Tumors
8%
Molecular Biomarkers
8%
Tumor Recurrence
8%
Bevacizumab
8%
Preoperative Patients
8%
Quantitative PCR
8%
Amide Proton Transfer-weighted Imaging
8%
Short-term Postoperative Outcomes
8%
Primary Tumor
8%
Radiation Dose Escalation
8%
In Situ Hybridization
8%
MRI-guided
8%
Cytomegalovirus
8%
Procaspase
8%
Physical Health-related Quality of Life
8%
Pharmacology, Toxicology and Pharmaceutical Science
Glioblastoma
45%
Neoplasm
34%
Temozolomide
29%
Clinical Trial
29%
Glioma
23%
Methotrexate
16%
Progression Free Survival
16%
Brain Tumor
15%
Biological Marker
13%
Rituximab
12%
Overall Survival
9%
Solid Malignant Neoplasm
9%
Chemoradiation Therapy
8%
Malignant Neoplasm
8%
Transforming Growth Factor
8%
Galunisertib
8%
Disease
7%
Tumor Recurrence
7%
Maximum Tolerated Dose
6%
Receptor
6%
Chemotherapy
5%
Procaspase 3
5%
Astrocytoma
5%
Oligodendroglioma
5%
Monotherapy
5%
Fluorine 18
5%
Lomustine
5%
Tumor Growth
5%
Adverse Event
5%
